Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06671613

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Led by VA Office of Research and Development · Updated on 2025-11-10

66

Participants Needed

4

Research Sites

270 weeks

Total Duration

On this page

Sponsors

V

VA Office of Research and Development

Lead Sponsor

I

Indiana University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

CONDITIONS

Official Title

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Eastern Cooperative Group (ECOG) performance status of 0 to 2
  • Newly diagnosed histologically or cytologically confirmed stage IV Non-Small Cell Lung Cancer (NSCLC) or locally advanced NSCLC not suitable for definitive therapy but eligible per investigator
  • Body Mass Index (BMI) of at least 19 kg/m2
  • Enrollment before starting standard care immunotherapy (PD-(L)1 inhibitor alone, specifically pembrolizumab) for stage IV NSCLC
  • Patients may have completed palliative or definitive radiation to oligometastatic disease prior to immunotherapy, after recovery from toxicities
Not Eligible

You will not qualify if you...

  • Self-reported weight loss of more than 10% in the 6 weeks before study entry
  • History of symptomatic hypoglycemia or uncontrolled diabetes
  • Prior therapies with insulin growth factor I (IGF-1) inhibitors like Linsitinib or Picropodophyllin
  • Current use of somatostatin
  • Concurrent use of immunosuppressive medications including sirolimus, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, dexamethasone, or cyclosporine
  • Significant food allergies preventing consumption of study-provided food
  • History or current uncontrolled medical or psychiatric conditions or therapies that could affect study participation or safety
  • Pregnant or lactating females are not eligible

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

VA Long Beach Healthcare System, Long Beach, CA

Long Beach, California, United States, 90822

Actively Recruiting

2

Jesse Brown VA Medical Center, Chicago, IL

Chicago, Illinois, United States, 60612

Actively Recruiting

3

Richard L. Roudebush VA Medical Center, Indianapolis, IN

Indianapolis, Indiana, United States, 46202-2884

Actively Recruiting

4

St. Louis VA Medical Center John Cochran Division, St. Louis, MO

St Louis, Missouri, United States, 63106-1621

Actively Recruiting

Loading map...

Research Team

S

Shadia Jalal, MD

CONTACT

A

Aleksandra Radovanovich, RN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here